Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).,Mycoses

当前位置： X-MOL 学术 › Mycoses › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Mycoses ( IF 4.9 ) Pub Date : 2020-05-12 , DOI: 10.1111/myc.13082
Markus Ruhnke ₁ , Oliver A Cornely _{2,

3,

4,

5} , Martin Schmidt-Hieber ₆ , Nael Alakel ₇ , Boris Boell ₂ , Dieter Buchheidt ₈ , Maximilian Christopeit ₉ , Justin Hasenkamp ₁₀ , Werner J Heinz ₁₁ , Marcus Hentrich ₁₂ , Meinolf Karthaus ₁₃ , Michael Koldehoff ₁₄ , Georg Maschmeyer ₁₅ , Jens Panse ₁₆ , Olaf Penack ₁₇ , Jan Schleicher ₁₈ , Daniel Teschner ₁₉ , Andrew John Ullmann ₂₀ , Maria Vehreschild _{2,

3,

21,

22} , Marie von Lilienfeld-Toal ₂₃ , Florian Weissinger ₁ , Stefan Schwartz ₂₄

Affiliation

Division of Haematology, Oncology and Palliative Care, Department of Internal Medicine, Evangelisches Klinikum Bethel, Bielefeld, Germany.
Department I of Internal Medicine, Faculty of Medicine, University of Cologne, Cologne, Germany.
ECMM Excellence Centre of Medical Mycology, Cologne, Germany.
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.
Klinik für Hämatologie und Onkologie, Carl-Thiem Klinikum, Cottbus, Germany.
Department I of Internal Medicine, Haematology and Oncology, University Hospital Dresden, Dresden, Germany.
Department of Hematology and Oncology, Mannheim University Hospital, Heidelberg University, Mannheim, Germany.
Department of Stem Cell Transplantation & Oncology, University Medical Center Eppendorf, Hamburg, Germany.
Clinic for Haematology and Medical Oncology with Department for Stem Cell Transplantation, University Medicine Göttingen, Göttingen, Germany.
Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany.
Hämatologie und Internistische Onkologie, Innere Medizin III, Rotkreuzklinikum München, München, Germany.
Department of Haematology & Oncology, Municipal Hospital Neuperlach, München, Germany.
Klinik für Knochenmarktransplantation, Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen (AöR), Essen, Germany.
Department of Hematology, Onclogy and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany.
Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen, Aachen, Germany.
Division of Haematology & Oncology, Department of Internal Medicine, Charité University Medicine, Campus Rudolf Virchow, Berlin, Germany.
Klinik für Hämatologie Onkologie und Palliativmedizin, Katharinenhospital, Stuttgart, Germany.
III. Medizinische Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany.
Department of Internal Medicine II, Julius Maximilians University, Würzburg, Germany.
Zentrum für Innere Medizin, Infektiologie, Goethe Universität Frankfurt, Frankfurt am Main, Deutschland.
Deutsches Zentrum für Infektionsforschung (DZIF), Standort Bonn-Köln, Deutschland.
Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
Division of Haematology & Oncology, Department of Internal Medicine, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany.

Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects.

中文翻译：

癌症患者侵袭性真菌病的治疗 - 德国血液学和肿瘤学会 (DGHO) 传染病工作组 (AGIHO) 2019 年修订建议。

侵袭性真菌病仍然是接受强化细胞毒治疗的癌症患者发病率和死亡率的主要原因。最合适的抗真菌治疗 (AFT) 的选择取决于怀疑或确定的真菌种类、患者的危险因素（例如粒细胞减少症的长度和深度）以及预期的副作用。

更新日期：2020-05-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>